Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Retinoids - Which dermatological indications will benefit in the near future?
Autore:
Zouboulis, CC;
Indirizzi:
Free Univ Berlin, Med Ctr B Franklin, Dept Dermatol, D-14195 Berlin, Germany Free Univ Berlin Berlin Germany D-14195 ermatol, D-14195 Berlin, Germany
Titolo Testata:
SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY
fascicolo: 5, volume: 14, anno: 2001,
pagine: 303 - 315
SICI:
1422-2868(200109/10)14:5<303:R-WDIW>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-TRANSPLANT RECIPIENTS; TAZAROTENE 0.1-PERCENT GEL; DOUBLE-BLIND; ACTINIC KERATOSES; TOPICAL TRETINOIN; DARIERS-DISEASE; PHASE-I; 13-CIS-RETINOIC ACID; 9-CIS-RETINOIC ACID; ACITRETIN THERAPY;
Keywords:
retinoids; clinical indications;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
90
Recensione:
Indirizzi per estratti:
Indirizzo: Zouboulis, CC Free Univ Berlin, Med Ctr B Franklin, Dept Dermatol, Fabeckstr 60-62, D-14195 Berlin, Germany Free Univ Berlin Fabeckstr 60-62 Berlin Germany D-14195 any
Citazione:
C.C. Zouboulis, "Retinoids - Which dermatological indications will benefit in the near future?", SKIN PH APP, 14(5), 2001, pp. 303-315

Abstract

Retinoids are compounds with pleiotropic functions and a relatively selective targeting of certain skin structures. They are vitamins, because retinol (vitamin A) is not synthesized in the body and must be derived from diet,but also hormones with intracrine activity, because retinol is transformedinto molecules that bind to nuclear receptors, exhibit their activity, andare subsequently inactivated. Retinoids exert their effects on target cells by binding and activating nuclear retinoid receptors. Retinoid receptors bind their ligands in form of dimers. Heterodimers can be formed between two different retinoid receptor molecules but also between retinoid X receptors and the vitamin D receptor as well as the triiodothyronin receptor. Thisfact indicates complex interactions between retinoids and further hormonalsignal transduction molecules. Interaction of retinoid receptors with transcriptional factors activated by other signal transduction mechanisms, e.g. AP-1, may provide dissociation of the retinoid effects. Retinoids can exhibit agonistic activity but also be neutral antagonists and inverse agonists. Topical and oral retinol, tretinoin, isotretinoin, and bexarotene, topical alitretinoin, retinaldehyde, motretinide, adapalene, tazarotene, and systemin acitretin compose the list of launched retinoids. Psoriasis and related disorders, congenital disorders of keratinization, acne, photoaging and hypovitaminosis A are classical approved indications of retinoid treatment, whereas cutaneous T-cell lymphoma, AIDS-associated Kaposi's sarcoma, acute promyelocytic leukemia and actinic lentigines were currently confirmed. In addition, retinoids have been successfully used in several other dermatoses, e.g. epithelial precanceroses and tumors, seborrhea, rosacea and acneiform dermatoses, lichen planus, eosinophilic folliculitis, condylomata accuminata, lichen sclerosus and atrophicus. Highly receptor selective molecules, retinoic acid receptor-beta -inducers, AP-1 complex antagonists, and inverse agonists will be probably lead the retinoid development in the near future. New, more effective and less toxic retinoids, alone or in combination with other drugs and new delivery systems may provide therapeutic solutions for benign and malignant proliferative skin diseases, such as psoriasis and nonmelanoma tumors, cancer chemoprevention and differentiation therapy. Copyright ((C)) 2001 S. Karger AG,Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 10:54:49